Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading 0.7% Higher – Here’s Why

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) shares rose 0.7% during trading on Monday . The stock traded as high as $25.77 and last traded at $25.77. Approximately 307 shares were traded during mid-day trading, a decline of 85% from the average session volume of 2,011 shares. The stock had previously closed at $25.59.

Amplify Weight Loss Drug & Treatment ETF Trading Down 0.1%

The stock has a market capitalization of $5.05 million, a PE ratio of 24.31 and a beta of 0.39. The firm’s 50-day simple moving average is $26.30 and its two-hundred day simple moving average is $25.24.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new position in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC bought a new position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.